Bayer will transition from Axeda to ThingWorx to continue delivering VirtualCARE® Remote Support services to connected customers
July 20, 2020
For several years, Bayer has relied on PTC’s Axeda platform to securely deliver VirtualCARE® Remote Support services to connected customer equipment and software through the cloud. PTC has announced that in the near future, it will no longer support Axeda, a first-generation platform. As a result, Bayer will be transitioning to ThingWorx, PTC’s next-generation connectivity platform, to continue to provide customers with VirtualCARE services while leveraging the latest available technology.
The transition from Axeda to ThingWorx is currently planned to occur in late Q3 2020.
What does my facility need to know about the transition to ThingWorx?
- Bayer will notify affected customers in advance of the scheduled migration date and again when the migration has been completed successfully. Please continue to visit this Information Technology Advisory web page for ongoing updates.
- During the migration, customers should expect no interruption to the operation of their Bayer equipment and software. Bayer anticipates that any disruption to customers’ VirtualCARE services during the migration will be minimal.
- Bayer’s transition to ThingWorx will not impact contract pricing or entitlements for customers with active Bayer Service Agreement Program(s).
- Customer facilities using IP address(es), as opposed to domain names, in their corporate firewall rules to allow Bayer to deliver VirtualCARE services should prepare for the ThingWorx server IP addresses to change as a result of this transition. Bayer will provide the new addresses in a follow-up communication.
- After the transition to ThingWorx, Bayer will continue to deliver VirtualCARE Remote Support services that offer the same levels of security that our customers have come to trust and depend on.
We are committed to supporting our customers through the transition from Axeda to ThingWorx. If you have immediate questions or concerns, please contact the Bayer Technical Assistance Center for support.
Ripple20 Cybersecurity Vulnerabilities
July 20, 2020
Bayer has performed an initial assessment of the recently cited Ripple20 vulnerabilities discovered in the Treck TCP/IP stack, which have the potential to affect any device running on an Intel-manufactured processor.
Ripple20 and Radimetrics™ Dose Management:
After thorough analysis, Bayer has determined that Ripple20 could pose a threat to the Radimetrics Dose Management application.
The Radimetrics application is deployed on a virtual machine running on the customer’s hardware. The threat depends on the actual hardware deployment of the application, and the vulnerability of the specific Intel chips and firmware. Intel has released patches for these vulnerabilities, and Bayer recommends that customers review the Intel Security Advisory for specific hardware that is impacted, in order to determine their best course of action.
The following Intel CVEs pertain to a potential Denial-of-Service attack specific to only IPv6 implementations. If a Denial-of-Service attack occurs, the Radimetrics application follows its standard recovery process.
The following CVEs pertain to information disclosure of DHCPv6 related data (network configuration data) on the local area network:
Ripple20 and Bayer Injection Systems:
Bayer is currently evaluating these vulnerabilities and assessing their potential to impact Bayer injection systems, including the MEDRAD® Stellant FLEX CT Injection System, the MEDRAD® Stellant CT Injection System with Certegra® Workstation, the MEDRAD® MRXperion MR Injection System, the MEDRAD® Intego PET Infusion System and any system connected to VirtualCARE™ Remote Support.
To complete its evaluation, Bayer is in contact with its suppliers to determine if there is any impact to these devices. In general, the threat depends on the actual hardware deployment and the Treck TCP/IP stack implementation. Additional information regarding these vulnerabilities can be found at the CERT Coordination Center.
Bayer prioritizes product security and will share additional updates related to the Ripple20 vulnerabilities as needed. Please continue to visit this Information Technology Advisory web page for the latest information.
Apache Tomcat and Radimetrics™ Radiation Dose Management
July 20, 2020
Bayer has performed a risk assessment of the end of life Apache Tomcat Webserver Version 8.0.24, which is currently utilized in Bayer’s Radimetrics™ Radiation Dose Management application.
As a result of the assessment, we have determined that there are currently no publicly known vulnerabilities that could result in risk to the Radimetrics application. Additionally, Radimetrics employs the following controls to further mitigate the potential for risk:
- User name and password authentication are required for data access
- System and data access are restricted to authorized users only
- Access to patient data is recorded in log files
- Special configurations are required to send certain data to specific clients
- SSL encryption on web connections can be implemented at the customer’s request
- Host computer isolation via Virtual Machine functionality and data loss prevention/disaster recovery via optional backups/snapshots are enabled
Bayer is planning a Radimetrics software upgrade, which is expected to be released in 2020. This upgrade will include updates to Apache Tomcat, among other software components, as well as an enhanced user interface and additional product features.
If you have additional questions about how this Apache Tomcat product lifecycle milestone impacts your Radimetrics software, please contact the Bayer Technical Assistance Center.
SweynTooth Cybersecurity Vulnerabilities
March 10, 2020
The U.S. Food and Drug Administration (FDA) recently notified the healthcare community about the SweynTooth family of cybersecurity vulnerabilities, which are associated with Bluetooth Low Energy wireless communication technology and have the potential to impact medical devices.
To read the full notification, please visit the FDA press announcement web page and select the below titled article from March 3, 2020:
FDA Informs Patients, Providers and Manufacturers About Potential Cybersecurity Vulnerabilities in Certain Medical Devices with Bluetooth Low Energy
Given this announcement, we want to assure you that Bayer injection systems do not utilize Bluetooth. Therefore, the SweynTooth vulnerabilities do not pose a threat to any fielded Bayer injection system.
Important Update - AVG AntiVirus Software used with Bayer devices operating on Microsoft® Windows 7
The purpose of this message is to provide you with an update on the Microsoft® Windows 7 to Windows 10 transition plan for your Bayer device.
As previously communicated, although Microsoft will support Windows Embedded Standard 7 Service Pack 1 through October 13, 2020, the current AVG AntiVirus software protection on Bayer devices running this version of Windows 7 will expire on January 31, 2020.
The Bayer Service team has been working to transition customers to Windows 10 in advance of the Windows Embedded Standard 7 Service Pack 1 end of support date to ensure that all compatible fielded devices receive ongoing security updates and antivirus protection. As a reminder, any Bayer device running Windows 7 is operating on Windows Embedded Standard Service Pack 1.
In the interim, to ensure that customer devices running Windows 7 do not experience a lapse in antivirus coverage, Bayer will take the following immediate actions:
Customers with a Certegra® Workstation or VirtualCARE™ Box operating on Windows 7 and actively connected to VirtualCARE™ Remote Support
- Beginning the week of January 20, 2020, Bayer will remotely deliver a security update to all customers with Windows 7 to extend AVG antivirus protection for one year. This update will occur virtually, and customers will not notice any changes to their operating system, nor will they be required to reboot their Bayer device. The security update will not impact or disrupt any patient procedures.
- This update doesn’t impact the Windows 10 migration, which will still occur before October 2020. This extended protection will ensure the continued functionality of the AVG software until product software on the device is updated to Windows 10.
Customers with a Certegra® Workstation or VirtualCARE™ Box operating on Windows 7 and not actively connected to VirtualCARE™ Remote Support
- As previously communicated, a Bayer Service representative will contact you to migrate your system to Windows 10 before October 13, 2020.
- If your Workstation isn’t connected to VirtualCARE™ Remote Support but is connected to your hospital network, please contact Bayer Service for an assessment of next steps related to the migration.
- If you have any other questions or concerns regarding the upgrade or your AVG software, please contact the Bayer Service at 1-877-229-3767.
- As previously communicated, the Certegra® box (legacy hardware used to enable informatics connectivity prior to the release of the Certegra® Workstation) reached its end of life on January 1, 2020. End of life means that Bayer will no longer offer service or support, including antivirus updates, on the installed base of Certegra® Boxes in the US.
Windows 10 Migration
Bayer remains committed to installing Microsoft® Windows 10 on all compatible fielded devices, which will provide customers with antivirus protection through Microsoft Windows Defender. The Microsoft Windows migration applies to all customers. The transition will happen either through a product software update or an equipment platform upgrade.
For more information regarding the transition to Windows 10 for Bayer devices, please refer to the Information Technology Advisory from October 29, 2019 below.
November 22, 2019
Bayer has performed an assessment of the recently announced URGENT/11 vulnerability, which affects VxWorks. VxWorks is the most widely used real-time operating system(RTOS) in the world, and Bayer uses it in some of our devices. The vulnerability resides in the VxWorks TCP/IP stack(IPnet), impacting all versions since version 6.5.
Based on our analysis, we have determined that no Bayer devices are affected by the URGENT/11 vulnerability, due to the versions that we employ in our devices.
Product security and safety are of tremendous importance to Bayer, and we will continue to monitor the situation and the associated activity and provide updates, as needed.
Support for Microsoft® Windows 7 is ending – understand the transition plan for your Bayer device
October 29, 2019
Microsoft® has announced an important product lifecycle milestone for its Windows 7 Operating System, which may have an impact on your Bayer device.
In 2020, Microsoft will discontinue support of Windows 7, which means that it will no longer provide security updates, software updates or technical support for the Operating System.
How does this milestone impact your Bayer device?
Bayer has decided that in order to effectively support fielded devices while providing customers with the latest Microsoft Operating System, it will proactively migrate all compatible* Windows-based Bayer devices to Windows 10.
If your facility has a Bayer device in service that is operating on Windows 7 or Windows XP, Bayer has a plan to support your transition to Windows 10, whether through a product software update or an equipment platform upgrade.
What is the transition plan for your Bayer device?
If your facility has one or more of the devices below in service, it is likely running on Windows 7 or Windows XP. Please click on the product links below to understand the detailed transition plan for your device.
- MEDRAD® Stellant CT Injection System with Certegra® Workstation running Certegra Software v4.4 or earlier
- MEDRAD® MRXperion Injection System with Certegra® Workstation running Certegra Software v4.4 or earlier
- VirtualCARE™ Remote Support hardware used with MEDRAD® Stellant Classic, MEDRAD® Spectris Solaris EP, MEDRAD® Mark 7 Arterion and MEDRAD® Avanta Injection Systems
- MEDRAD® Intego 200 PET Infusion System
- Certegra Box connected to a MEDRAD® Stellant Classic CT Injection System
In addition, please be aware that due to the transition to Windows 10, the current antivirus protection on Bayer devices running Windows 7 and Windows XP will not be renewed beyond January 2020. †
Don’t see your Bayer device on the list?
Some Bayer devices are already operating on Microsoft Windows 10 and others do not operate on a Microsoft Windows-based platform. Therefore, they are not affected by Windows 7 end of support:
- MEDRAD® Stellant FLEX CT Injection System
- Standalone MEDRAD® Stellant Classic, MEDRAD® Spectris Solaris EP, MEDRAD® Mark 7 Arterion and MEDRAD® Avanta Injection Systems
- MEDRAD® EnVision, MEDRAD® Spectris and MEDRAD® Provis Injection Systems
Bayer is committed to helping your facility through the transition from Windows 7 to Windows 10. Please continue to visit Bayer in Radiology’s Information Technology Advisory web page to receive ongoing updates on the migration process or contact Bayer Service at 1-877-229-3767 for support.
*The Certegra Box is a legacy device that predates Bayer’s three generations of Certegra® Workstation technologies. As such, it is not compatible with Windows 10. Bayer offers several upgrade pathways to assist customers with the transition from the Certegra Box to the Certegra® Workstation 3.0. Please contact your local Bayer Sales Representative for more information.
† The MEDRAD® Intego 200 PET Infusion System does not utilize the same antivirus software as the MEDRAD® Stellant CT Injection System, the MEDRAD® MRXperion Injection System and the VirtualCARE™ Remote Support hardware. As such, the timeline for migration to Windows 10 for the Intego 200 product line is different. Please refer to the product links above for more information.
Information on Orangeworm vulnerability
April 30, 2018
Bayer Radiology has performed an assessment of the below listed Orangeworm vulnerability, and, based on the current understanding and our internal research, we have determined that there is no immediate safety or security threat to Bayer Radiology medical devices, including MEDRAD® Stellant and MEDRAD® MRXperion control room units (Certegra® Workstations), Certegra® and VirtualCare™ devices, MEDRAD® Intego, and Certegra® Connect CT. This is due to the fact that the current primary attack vector is through phishing techniques, which are not supported on these Bayer Radiology medical devices. Bayer Radiology medical devices are not a primary entry point for a phishing-based attack such as Orangeworm, but are highly dependent on the strength of the network on which they are deployed. Bayer Radiology recommends regular network maintenance and patch updates to mitigate vulnerabilities, such as Orangeworm.
The Bayer Radiology Radimetrics™ Enterprise Platform is not impacted by this vulnerability, as it is a Linux-based system and does not rely on MS Windows.
We will continue to monitor the situation and the associated activity and provide updates as needed.
|Potential Orangeworm vulnerability:|
Trojan-type virus aﬀecting MS Windows systems, which may open a back door on the compromised system and download potentially malicious files.
Information on Meltdown and Spectre security issue
January 15, 2018
Bayer Radiology is committed to product safety and security, and an integral element of the Bayer cyber response process is the ongoing global monitoring for cybersecurity signals. Bayer Radiology maintains a testing and monitoring infrastructure, complete with assessment and vulnerability analysis tools, that enables continuous awareness of industry threats. Currently, our Bayer Radiology CyberSecurity team is conducting risk and vulnerability assessments of the recently discovered Meltdown and Spectre vulnerabilities in order to determine potential impact on Bayer Radiology products.
Bayer Radiology will continue to monitor activity and updates associated with the Meltdown and Spectre vulnerabilities, including mitigation solutions being released by various entities. Bayer will continue to post updates regarding this security issue on this website. Customers
requiring further assistance should call Bayer at 1-877-229-3767.